Beacon Select System™ opens new technological chapter in Mabion
Cell Line Development begins with transfection of host cells with recombinant plasmids or cell fusion in the case of hybrids. Beacon Select System™ automaticly select clones with the highest titer and assures their monoclonality. The selection proper is done on a mini scale and depends on the specifics of the process (productivity of the cell line, timing of cell division, complexity of the molecule structure).
We are thrilled to announce that Mabion S.A. has recently acquired the cutting-edge Beacon Select™ System for cell line development (CLD). This optofluidic system will further improve our proficiency in identifying the top-producing clones with favorable product quality attributes, ensuring the process completion within just 5 days of cloning.
Key features of the Beacon Select System include:
- Advanced technology: Patented Opto-ElectroPositioning (OEP™) technology uniquely enables the selective movement of cells using low intensity light to position then into NanoPen™ chambers (0.2 – 2 nanoliter holding chambers for individual cells).
- Quality assays: The placement of a single cell in a NanoPen™ chamber allows a game-changing experimentation and further interrogation on the single-cell level by a variety of different assays – binding assays, fluorescence assays, morphological and phenotypic assays.
- Time-saving throughput: The Beacon Select™ ensures throughput scalability without compromising efficiency. They enable us to select clones with favorable product quality attributes, reducing overall costs, improving cloning efficiency, and significantly shortening timelines by identifying top clones for scale-up.
- Environmental friendliness: By significantly reducing the use of reagents, single-use materials and waste generated, this environmentally friendly device significantly reduces Mabion’s carbon footprint and underlines its commitment to responsible and sustainable biotechnology practices.
This automated process minimizes human intervention, encompassing enrichment, cloning, culture, assay, selection, and recovery in a single streamlined workflow. This stands in stark contrast to conventional clone selection methods, where multiple steps must be performed sequentially on various instruments.
We extend our gratitude to everyone involved in this milestone project and appreciate the ongoing support from our partners from Bruker. Together we drive innovation in biotechnology and open new opportunities for our customers!